Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    36
  • sponsor
    City of Hope Medical Center
Updated on 27 June 2021

Summary

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). T cells are infection fighting blood cells that can kill cancer cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize CD19, a protein on the surface of the cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19 positive cancer cells. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CD19 CAR T cells together with acalabrutinib may kill more cancer cells.

Description

PRIMARY OBJECTIVES:

I. Evaluate the safety of adding CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19 CAR T cells) to acalabrutinib treatment. (Safety Lead-in) II. Estimate the complete response (CR) rate within 6 months after adding CD19 CAR T cells to acalabrutinib treatment. (Phase 2)

SECONDARY OBJECTIVES:

I. Assess best response, time to and duration of CR. II. Estimate the 1-year progression free survival (PFS) rate and overall survival (OS).

III. Describe the full toxicity profile.

EXPLORATORY OBJECTIVES:

I. Assess CD19-CAR T cell persistence. II. Assess CD19-CAR T cell activity as measured by CD19 B cell aplasia. III. Describe the duration of CR from completion of acalabrutinib. IV. Describe immunogenicity of CD19-CAR T cells in the presence of the BTK inhibitor.

V. Characterize CD19 expression on tumor cells. VI. Describe cytokine profile after CD19-CAR T cell infusion. VII. Determine BTK and PLCG2 mutational status prior to treatment.

OUTLINE

Patients receive acalabrutinib orally (PO) twice daily (BID) on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells intravenously (IV) on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.

After completion of study treatment, patients are followed up at 3, 6 and 12 months, then yearly for up to 15 years post CAR T cells infusion.

Details
Condition Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Treatment acalabrutinib, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Clinical Study IdentifierNCT04484012
SponsorCity of Hope Medical Center
Last Modified on27 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All participants must have the ability to understand and the willingness to sign a written informed consent
Participants must agree to allow the use of archival tissue from diagnostic tumor biopsies
If unavailable, exceptions may be granted with study principal investigator (PI) approval
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky Performance Status (KPS) >= 70%
Documented CD19+ mantle cell lymphoma (MCL) by flow cytometry or immunohistochemistry (IHC) (from biopsy) if prior CD19 directed therapy was previously used
Participants must be currently receiving acalabrutinib and have been taking acalabrutinib for between 3 and 7 months prior to initiating screening procedures on the study and
Must have failed at least 1 prior regimen before acalabrutinib (not including single-agent corticosteroids)
Best response to acalabrutinib therapy is MRD+ CR, partial response (PR) or stable response (SD) at the time of screening
Must have measurable disease by computed tomography (CT) scan (>= 1.5 cm) or evidence of blood or bone marrow involvement
No contraindications to leukapheresis, steroids or tocilizumab
Total serum bilirubin =< 2.0 mg/dL (performed within 28 days prior to enrollment)
Participants with Gilbert syndrome may be included if their total bilirubin is >= 3.0 x upper limit of normal (ULN) and direct bilirubin =< 1.5 x ULN (performed within 28 days prior to enrollment)
Aspartate aminotransferase (AST) < 3 x ULN (performed within 28 days prior to enrollment)
Alanine aminotransferase (ALT) < 3 x ULN (performed within 28 days prior to enrollment)
Creatinine clearance of >= 50 mL/min per the Cockcroft-Gault formula (performed within 28 days prior to enrollment)
International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN (performed within 28 days prior to enrollment)
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 28 days prior to enrollment)
Female of childbearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Cardiac function (12 lead-electrocardiogram [ECG]): corrected QT (QTc) must be =< 480 msec
Left ventricular ejection fraction > 40%
Oxygen saturation 92% or above at room air or diffusion capacity of the lung for carbon monoxide (DLCO) of 40% of best predicted
Participants of reproductive potential must agree to use highly effective birth control methods throughout therapy and for 2 months after final CAR T cell infusion and/or 2 days after final acalabrutinib dose, whichever is later

Exclusion Criteria

Allogeneic hematopoietic cell transplantation (HCT) within the last 6 months
Autologous HCT within the last 3 months
Prior failure of any BTK inhibitor therapy. (Participant WILL be allowed if they have switched to acalabrutinib due to intolerance of ibrutinib, and if ibrutinib therapy was =< 3 months)
Participants known to have mutations associated with resistance to BTK inhibitors from prior studies
Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (i.e., prednisone =< 7.5 mg /day, or hydrocortisone =< 20 mg /day) is allowed. During study participation, participants may receive systemic corticosteroids as needed for treatment-emergent comorbid conditions
Approved anti-cancer therapies other than acalabrutinib are not allowed after enrollment, with the exception of steroids or involved field radiation to control progressive disease during cell manufacturing, prior to lymphodepletion/start of protocol therapy
Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to histamine (H2)-receptor antagonists or antacids are eligible for enrollment to this study
Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer
Unable to discontinue anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of leukapheresis and remain off through end of study treatment
Class III/IV cardiovascular disability according to the New York Heart Association classification. Subjects with controlled, asymptomatic atrial fibrillation can enroll
Participants with clinically significant arrhythmia or arrhythmias not stable on medical management
Active auto-immune disease requiring systemic immunosuppressive therapy, including uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
Suspected or confirmed progressive multifocal leukoencephalopathy (PML)
Requires major surgical procedure within 28 days prior to first dose of study drug. If a subject has major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug
Participants with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
Known history of drug-specific hypersensitivity or anaphylaxis to either study agent
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass
Known bleeding disorders (e.g., von Willebrand's disease or hemophilia)
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of other malignancies, except for the following: malignancy surgically resected (or treated with other modalities) with curative intent, adequately treated in situ carcinoma of the breast or cervix uteri, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; early stage prostate cancer on expectant management; malignancy treated with curative intent with no known active disease present for >= 3 years
Lactating women
Active chronic graft-versus-host disease (GVHD) post-allogeneic HCT
Uncontrolled active infection
Human immunodeficiency virus (HIV) positive or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment
Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR) result. Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded
Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded
Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note